TNF inhibitors
Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis
... of TNF inhibitors in the elderly ...of TNF inhibitors in a different ...of TNF inhibitors [21–23], whereas other studies noted a positive influence of comorbidities on the drug ...
8
Efficacy and safety of tabalumab, an anti BAFF monoclonal antibody, in patients with moderate to severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double blind, placebo controlled, phase 3 study
... to TNF inhibitors, tabalumab was administered as either a 30 mg or 80 mg intravenous infusion at weeks 0, 3 and 6, 17 while the current phase 3 study evaluated two subcutaneous (SQ) tabalumab doses of 120 ...
9
Safety of TNF inhibitors in adolescents and children
... (TNF) inhibitors in children, reviews the pharmacology of these agents, and reviews and summarizes the current safety information available for etanercept, adalimumab, and ...infliximab. TNF ...
8
Non inferiority of dose reduction versus standard dosing of TNF inhibitors in axial spondyloarthritis
... to TNF inhibitor (TNFi) treatment; severe presented as proportion (95% CI) of patients with at least one severe reported AE and/or infection according to standard definitions (fatal or life-threatening, required ...
10
Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date
... events. TNF-α has been shown to have an important role within the central nervous system; its properties include activation of microglia and astrocytes, influence on blood–brain barrier permeability, and ...
19
Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
... Adults with JIA are a heterogeneous group, and the effects of tumour necrosis factor inhibitor TNFi therapies are not well described.. This analysis aims to describe treatment outcomes a[r] ...
9
Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non TNF inhibitors?
... continuation of biologics for RA when used as first or second biologic in a clinical practice setting, identified predictors of discontinuation and compared discontinu- ation rates betwe[r] ...
11
Safety of TNF-α inhibitors during IBD pregnancy: a systematic review
... Compared with the other two TNF inhibitors ap- proved for CD, the human data on pregnancy outcomes in mothers treated with CZP during pregnancy are more limited. In three case reports where CZP injections ...
13
Reduced Skin Blistering in Experimental Epidermolysis Bullosa Acquisita After Anti-TNF Treatment
... of TNF in skin, as determined by real-time polymerase chain reaction (PCR) and ...increased TNF expression is of functional relevance in experimental EBA, we inhibited TNF function using the soluble ...
9
Bone and TNF in rheumatoid arthritis: clinical implications
... with TNF inhibitors was able to arrest systemic bone loss assessed by bone mineral density and bone turnover markers, but there is scarce evidence of a clinically meaningful effect of TNF inhibition ...
6
Comparison of Real World Outcomes of Infliximab versus Adalimumab in Biologic Naïve Korean Patients with Ulcerative Colitis: A Population Based Study
... these TNF-α inhibitors are approved only for UC patients with moderate to severe activity (Mayo score 6 to 12 and en- doscopy subscore ≥2) in South Korea, it seems very unlikely that non-UC patients would ...
8
<p>Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database</p>
... transmembrane TNF 16–20 and Fc receptor-expressing ...transmembrane TNF, and showed that the degree of cell binding was 3-fold greater with in fl iximab or adalimumab than with etanercept or ...with ...
7
Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-alpha Inhibitors in Rheumatoid Arthritis
... In clinical practice, approximately one-third of patients with rheumatoid arthritis (RA) respond insufficiently to TNF-α inhibitors (TNFis). The aim of the study was to explore the use of a metabolomics to ...
18
TNF-α inhibitors: are they carcinogenic?
... With TNF- α playing a pivotal role in immune function and inflammation, it has also been associated with ...population. TNF- α is intricately involved in immunomodulation. TNF family receptor CD30 is ...
7
Group A Streptococcus Brain Abscess in a Patient on Adalimumab Therapy
... with TNF-a inhibitors but no reports of unusual streptococcal abscess ...of TNF-a inhibitors could have predisposed him to his ...of TNF-a inhibitors, our patient lacked typical ...
6
TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism
... that TNF- a markedly decreased expression of PLD1, and that cera- mide-synthesis inhibitors rescued its expression, suggest- ing that PLD1 is one major target of ceramide in this signaling ...these ...
19
Insulin augments tumor necrosis factor-alpha stimulated expression of vascular cell adhesion molecule-1 in vascular endothelial cells
... Cells were grown in CGM until 75% confluence. Growth medium was replaced with serum-free medium (SFM) for 24 hours. Cells were incubated in SFM without or with insulin or TNF-alpha alone or in combination for ...
10
The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF alpha
... Our findings suggest that inhibition of IKK represents a possible strategy to overcome the TNFα/MITF mediated survival signals that protect melanoma cells from MEK inhibition. We therefore assessed whether IKKi mediated ...
29
Studying activity and toxicity of different TNF-alpha inhibitors in controlling patients with active ulcerative colitis
... 1994). TNF-alpha production is expanded in mucosal macrophages detached from the lesion, and it shown in expanded levels in the blood circulation, mucosal tissue, and stools of those with ulcerative colitis ...
10
Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept
... Infliximab (3 mg/kg, iv, at 0/2/6 weeks and every 6 weeks thereafter) was started in combination with MMF and prednisolone with excellent prompt clinical and laborator- ial response. Coinciding with clinical symptoms ...
5